Restart Life Sciences Corp. is a listed company. Its directors and officers file their transactions with SEDI. Between 20 October 2025 and 20 October 2026, 3 insiders published 22 filings.
Purchases and sales both appear in the filings: 12 purchases (2 insiders, €125k) and 1 sale (1 insider, €123k). Purchases outweigh sales by €2,319. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 2 senior executives. At €123k, the sale published on 21 November 2025 by Loutskou, Steve is the largest of the period.
For context, the typical company on the same exchange (median of 2,468 companies) published 12 filings over the same period, against 22 filings here. Looking back to 2025, when coverage begins, insiders filed 12 purchases and 1 sale.
The latest purchase dates back some time: it was published 74 days ago, on 7 August 2026. Typically, a trade is published a median of 2 days after it takes place. This delay matters because a trade only becomes useful information once it is public.
Source: insider filings from SEDI. Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended February 2026 · cache
22 of 22 declarations
Restart Life Sciences Corp. is a company listed on the Toronto Stock Exchange, focused on developing innovative solutions for the life sciences sector.